{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"Disease Progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}],"title":"Censored"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}],"title":"PFS at 6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"PFS at 12 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Per International Myeloma Working Group Response Criteria, progression/progressive disease is defined as increase of \\>25% from lowest response value in any 1 of the following: serum M-component (the absolute increase must be \\>0.5 g/dL)4 and/or urine M-component (the absolute increase must be \\>200 mg/24 h) and/or; only in patients without measurable serum and urine M-protein, the difference between involved and uninvolved FLC levels. The absolute increase must be \\>10 mg/dL; only in patients without measurable serum and urine M-protein and without measurable disease by FLC levels; bone marrow plasma cell percentage (absolute % must be ≥10%); definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder.","groups":[{"description":"SL-401 7 µg/kg/day in combination with pomalidomide and dexamethasone","id":"OG000","title":"SL-401 7 µg/kg/Day"},{"description":"SL-401 9 µg/kg/day in combination with pomalidomide and dexamethasone","id":"OG001","title":"SL-401 9 µg/kg/Day"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 12 Months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Participants"}